Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics
Heterogeneous response to efgartigimod in real-world experience with myasthenia gravis: Predictors and treatment strategies.
Lior Fuchs, Ifat Vigiser, Hadar Kolb, Keren Regev, Vivian E Drory, Amir Dori, David Magalashvili, Tal Caller, Gilad Kenan, Yana Mechnik Steen, Mark Hellmann, Adi Wilf-Yarkoni, Tal Friedman Korn, Adi Vaknin-Dembinsky, Alaa Bsoul
Published: 202610.1016/j.neurot.2026.e00837
Abstract
Efgartigimod is an established therapy for acetylcholine receptor antibody-positive generalized myasthenia gravis, yet real-world data on long-term overall responsiveness, response patterns, steroid-sparing effects, bridging therapy use, and predicto…
Preview only. Read the full abstract at the source